No Intrathecal Morphine
Phase 3Small molecule
No Intrathecal Morphine is one of 52 small molecule programs targeting Obstructive Sleep Apnea. It is currently in Phase 3.
2
Indications
2
Total Trials
1
Active Trials
51
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
52 competitors in Obstructive Sleep Apnea
#DrugCompanyPhaseTrials
1Diamox
TevaApproved
Aricept
EisaiApproved
Humira
NovartisApproved
Aldactone
PfizerApproved
Rozerem
TakedaApproved
Singulair
OOrganon and Co
Approved
Provigil
NNuvo Research GmbH
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Effexor
WWyeth-Lederle Vaccines
Approved
Raldesy
PPragma
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for No Intrathecal Morphine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversity of Toronto